Eledon Pharmaceuticals' Tegoprubart Shows Promise in Transplantation Therapies
核心洞察
Eledon Pharmaceuticals completed Phase 2 BESTOW trial enrollment for tegoprubart in kidney transplantation (搜索), with topline results expected in Q4 2025.
Updated Phase 1b data supports tegoprubart's safety and tolerability in preventing kidney transplant rejection, showing stable eGFR in patients.
Initial data from a UChicago Medicine trial indicates tegoprubart may enable insulin independence in type 1 diabetes (搜索) patients post-islet transplantation.
Eledon Pharmaceuticals is making strides with its investigational drug, tegoprubart, across various transplantation settings. The company has completed enrollment in the Phase 2 BESTOW trial, evaluating tegoprubart for the prevention of organ rejection in kidney transplant recipients, four months ahead of schedule. Topline results are anticipated in the fourth quarter of 2025.
Tegoprubart's Clinical Progress
At the American Transplant Congress, Eledon presented updated data from an ongoing Phase 1b open-label trial assessing tegoprubart in kidney transplant patients. The data from 13 participants demonstrated that tegoprubart was generally safe and well-tolerated. The overall mean estimated glomerular filtration rate (eGFR) was 70.5 mL/min/1.73m2 at all reported time points after day 30 post-transplant. Notably, two participants who completed over 12 months on therapy post-transplant showed mean eGFRs above 90 mL/min/1.73m2 at one year.
Potential in Islet Cell Transplantation
Eledon also announced positive initial data from the first three islet transplant recipients with type 1 diabetes (搜索) treated with tegoprubart as part of an immunosuppression regimen at the University of Chicago Medicine’s Transplant Institute. The data suggested the potential for insulin independence using an anti-CD40L monoclonal antibody immunosuppression therapy without tacrolimus, the current standard of care.
Financial Stability and Future Milestones
"2024 was a transformative year for Eledon as we achieved multiple key clinical milestones for tegoprubart across kidney, islet cell, and xenograft transplantation," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. The company completed two financings, totaling $135 million in gross proceeds, expected to support operations through the end of 2026.
Looking ahead, Eledon anticipates reporting updated interim clinical data from the Phase 1b and long-term efficacy extension studies of tegoprubart in kidney transplantation (搜索) in the summer of 2025. Additionally, longer-term follow-up results from the UChicago Medicine Transplant Institute trial for pancreatic islet transplantation in type 1 diabetes (搜索) patients are expected in 2025.
About Tegoprubart
Tegoprubart is an anti-CD40L antibody with high affinity for the CD40 Ligand, a target involved in both adaptive and innate immune cell activation. Eledon is exploring tegoprubart's potential in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (搜索) (ALS).